Vical (VICL) Said Its H1N1 Vaccine Shows 100% Response In Mice and Rabbits
More News related to VICL
- Vical (VICL) Misses Q3 EPS by 1c; Revenues Above Consensus
- Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Vical to Present at BIOCOM Investor Conference
- Vical (VICL) Reports Publication of Two Articles About Vaxfectin
Vical Incorporated (Nasdaq: VICL) said its vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose vaccine regimen.
In addition, at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. The company is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.
Related Categories
FDAMomentum Movers
Stocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
